Notes

Market potentials of robot systems within health care science: investigation Avatera automatic system.
A liver metastasis from a primary gastric cancer (LMGC) is relatively common and results in an extremely poor prognosis due to a lack of effective therapeutics. We here demonstrate in a clinically-relevant mouse model that an α-radioimmunotherapy (α-RIT) approach with astatine-211-labeled-trastuzumab (211At-trastuzumab) has efficacy against LMGCs that are positive for human epidermal growth factor receptor 2 (HER2). Methods211At was produced in a cyclotron via a 209Bi (α, 2n) 211At reaction. 211At-trastuzumab was subsequently generated using a single-step labelling method. NCI-N87 cells (HER2-positive human GC cells) carrying a luciferase gene were intrasplenically transplanted into severe combined immunodeficiency mice to generate a HER2-positive LMGC model. A bio-distribution study was then conducted through the intravenous injection of 211At-trastuzumab (1 MBq) into these LMGC xenograft mice. In parallel with this experimental therapy, PBS, intact trastuzumab or 211At-non-specific human IgG (1MBq) were injer, liver function, or kidney parameters were observed in the 211At-trastuzumab group. Microdosimetric studies further revealed that 211At-trastuzumab had been delivered at an 11.5- fold higher dose to the LMGC lesions compared to the normal liver. Conclusion α-RIT with 211At-trastuzumab has considerable potential as an effective and safe therapeutic option for LMGC.Introduction Tens of different PSMA targeting radiopharmaceuticals for both imaging and therapy have been synthesized. Although variability in biodistribution and affinity for binding to the PSMA receptor between different PSMA targeting radiopharmaceuticals are known, little is known about the clinical implications of those variabilities. Therefore in this study differences in inter-reader agreement and detection rate between two regularly used 18F-labeled PSMA-receptor targeting radiopharmaceuticals [18F]-DCFPyL and [18F]-PSMA-1007 were analyzed. Material and Methods One hundred and twenty consecutive patients scanned with [18F]-PSMA-1007 were match-paired with 120 patients scanned with [18F]-DCFPyL. All 240 PET/CTs were reviewed by two readers and scored according to PSMA-RADS reading criteria for PSMA PET/CT. this website Inter-reader agreement and detection rate of suspected lesions were scored for different anatomical locations including prostate/prostatic fossa, lymph nodes, bone, and other locations. Results Large equality between [18F]-DCFPyL and [18F]-PSMA-1007 was found; however, some clinically relevant and statistically significant differences were observed. [18F]-PSMA-1007 detected suspected prostatic/prostatic fossa lesions in a higher proportion of patients and especially in the subcohort of patients scanned for biochemical recurrence. [18F]-DCFPyL and [18F]-PSMA-1007 showed equal ability for detection of suspected lymph nodes, although inter-reader agreement for [18F]-DCFPyL was higher. [18F]-DCFPyL showed less equivocal skeletal lesions and higher inter-reader agreement for skeletal lesions. Conclusion Clinical relevant differences, which may account for diagnostic dilemmas, were observed between of [18F]-DCFPyL and [18F]-PSMA-1007. Those findings encourage further studies, as they may have consequences for selection of the proper PSMA targeting radiopharmaceutical.Purpose To investigate the prognostic value of 18F-FDG PET/CT parameters in melanoma patients before beginning anti-PD-1 therapy. Methods Imaging parameters including SUVmax, metabolic tumor volume (MTV), and bone marrow to liver SUVmean ratio (BLR) were measured from baseline PET/CT in 92 patients before the start of anti-PD-1 therapy. Association with survival and imaging parameters combined with clinical factors was evaluated. Clinical and laboratory data between high (> median) and low (≤ median) BLR groups were compared. Results Multivariate analyses demonstrated that BLR was an independent prognostic factor for PFS and OS (P = 0.017, P = 0.011, respectively). The high BLR group had higher levels of white blood cell count/neutrophil count and C-Reactive Protein than the low BLR group (P less then 0.05). Conclusion Patients with high BLR were associated with poor PFS and OS, potentially explained by evidence of systemic inflammation known to be associated with immunosuppression.161Tb has similar decay properties as 177Lu but, additionally, emits a substantial number of conversion and Auger electrons. The aim of this study was to apply 161Tb in a clinical setting and to investigate the feasibility to visualize the physiological and tumor biodistribution of 161Tb-DOTATOC. Methods161Tb was shipped from Paul Scherrer Institute, Switzerland, to Zentralklinik Bad Berka, Germany, where it was used for the radiolabeling of DOTATOC. In two separate studies, 596 MBq and 1300 MBq 161Tb-DOTATOC were administered to a 35-year-old male patient with metastatic, well differentiated, non-functional malignant paraganglioma and a 70-year-old male patient with a metastatic, functional neuroendocrine neoplasm of the pancreatic tail, respectively. Whole-body planar γ-scintigraphies were acquired over a period of several days for dosimetry calculations. SPECT/CT images were reconstructed, using a recently-established protocol and visually analyzed. Patients were checked for adverse events after application of 161Tb-DOTATOC. Results The radiolabeling of DOTATOC with 161Tb was readily achieved with high radiochemical purity suitable for patient application. Planar images and dosimetry provided the expected time-dependent biodistribution of 161Tb-DOTATOC in liver, kidneys, spleen and urinary bladder. SPECT/CT images were of high quality and visualized even small metastases in the liver and bones. Application of 161Tb-DOTATOC was well tolerated and no related adverse events were reported. Conclusion This study demonstrated the feasibility to image even small metastases after injection of relatively low activities of 161Tb-DOTATOC using γ-scintigraphy and SPECT. Based on this essential first step to translate 161Tb to clinics, further efforts will be directed towards the application of 161Tb for therapeutic purposes.
My Website: https://www.selleckchem.com/products/abtl-0812.html